Clinical Trial Update: Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing LIK066 for reducing fatty content in livers of obese patients with non-alcoholic steatohepatitis (NASH); study completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis
• Obesity

Drugs mentioned

• LIK066 (LIK066)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Obese Patients With Non-alcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2021-01-06